Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Akero Therapeutics Inc
AKRO
Healthcare
Biotechnology
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing...
phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:AKRO)
New Post
View:
Posts & Comments
Threaded Posts
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Dec 15, 2024 11:00am
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Th
News; $AKRO Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to ConnectNEW YORK CITY, NY / ACCESSWIRE / December 15, 2024 / Bronstein
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jul 15, 2024 1:32pm
This Analyst Sees Potential Downside In Eli Lilly, Adjusts M
JUST IN: $AKRO This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges | BenzingaCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the
...more
Q Precious & Battery Metals Refines Targeting For Diamond Drilling La Corne South Project
posted Jan 06, 2025 9:00am by
Q Precious & Battery Metals Corp.
-
|
Continued drilling is planned for early 2025. The company’s geologic team has continued to investigate the geophysical survey data, including 3-dimensional modeling of the TDEM survey results. The successful drilling of the TDEM anomaly at holes 24LCS-01 to 24LCS-03 indicates that these targets are of primary interest for further testing. The geophysics shows a cluster of ...read more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jun 21, 2024 1:30pm
AKRO Investors Have Opportunity to Lead Akero Therapeutics,
Just In: $AKRO AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm | BenzingaLOS ANGELES, June 21, 2024 (GLOBE NEWSWIRE) -- The Schall
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Mar 04, 2024 1:15pm
Akero Therapeutics Reports Positive Phase 2b HARMONY Study D
NEWS: $AKRO Akero Therapeutics Reports Positive Phase 2b HARMONY Study Data2024-03-04 07:22:02 ET DENVER, Colo., Mar 04, 2024 ( 247marketnews.com )- Akero Therapeutics, Inc. (NASDAQ: AKRO ) released
...more
(192)
•••
scarlet1967
X
View Profile
View Bullboard History
Post by
scarlet1967
on May 26, 2021 7:39pm
Please take a look
https://www.change.org/p/fda-and-ema-improving-the-public-health?recruiter=1170861947&recruited_by_id=6f0edee0-47cf-11eb-a646-01144e979023&utm_source=share_petition&utm_medium=copylink&
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.